Login to Your Account



Evotec Options Narrow on Smoking Trial Miss

By Cormac Sheridan


Wednesday, April 22, 2009
Evotec AG's near-term partnering options narrowed on news that its smoking cessation drug EVT 302 failed to demonstrate efficacy in a Phase II proof-of-concept trial involving 414 smokers. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription